The estimated Net Worth of Reed N Wilcox is at least 3.5 百万$ dollars as of 14 November 2022. Reed Wilcox owns over 174,912 units of Clene Nanomedicine stock worth over 3,502,633$ and over the last 4 years Reed sold CLNN stock worth over 0$.
Sign up
Reed Wilcox CLNN stock SEC Form 4 insiders trading
Reed has made over 3 trades of the Clene Nanomedicine stock since 2022, according to the Form 4 filled with the SEC. Most recently Reed exercised 174,912 units of CLNN stock worth 26,237$ on 14 November 2022.
The largest trade Reed's ever made was exercising 253,000 units of Clene Nanomedicine stock on 20 January 2022 worth over 37,950$. On average, Reed trades about 75,416 units every 43 days since 2021. As of 14 November 2022 Reed still owns at least 575,145 units of Clene Nanomedicine stock.
You can see the complete history of Reed Wilcox stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Reed Wilcox's mailing address?
Reed's mailing address filed with the SEC is 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121.
Insiders trading at Clene Nanomedicine
Over the last 4 years, insiders at Clene Nanomedicine have traded over 1,293,164$ worth of Clene Nanomedicine stock and bought 19,236,803 units worth 21,152,263$ . The most active insiders traders include David J Matlin、Chidozie Ugwumba、Alison Mosca. On average, Clene Nanomedicine executives and independent directors trade stock every 26 days with the average trade being worth of 2,786,272$. The most recent stock trade was executed by Robert Dee Etherington on 29 July 2024, trading 27,320 units of CLNN stock currently worth 81,960$.
What does Clene Nanomedicine do?
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.
What does Clene Nanomedicine's logo look like?
Complete history of Reed Wilcox stock trades at Clene Nanomedicine
Clene Nanomedicine executives and stock owners
Clene Nanomedicine executives and other stock owners filed with the SEC include:
-
Robert Etherington,
CEO, Pres & Director -
Robert Etherington MBA,
CEO, Pres & Director -
Mark G. Mortenson,
Co-Founder & Chief Science Officer -
Dr. Robert Glanzman M.D.,
Chief Medical Officer -
Dr. Tae Heum Jeong,
Consultant -
Morgan R. Brown C.P.A., CPA, M.B.A., MBA,
Chief Financial Officer -
Mary Anne Mcneil,
Head of HR -
Michael Hotchkin,
Chief Devel. Officer -
Jerry Miraglia J.D.,
Gen. Counsel & Corp. Sec. -
Dr. Jeong Ted,
Chief Financial Officer -
Chidozie Ugwumba,
10% owner -
Matthew Kiernan,
-
Arjun Jj Desai,
-
Vallerie Mc Laughlin,
-
Shalom Jacobovitz,
-
Tae Heum Jeong,
Chief Finance Officer -
Alison Mosca,
-
David J Matlin,
-
Mark Mortenson,
Chief Science Officer -
Robert Glanzman,
Chief Medical Officer -
Fiona Costello,
-
Reed N Wilcox,
-
Robert Dee Etherington,
Chief Executive Officer -
John Henry Stevens,
-
Jonathon Gay,
-
Morgan R Brown,
Chief Financial Officer -
Resonance Llc General,
10% owner